BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

▤ Summary

BeOne Medicines reported positive Phase 3 survival data for ZIIHERA-based regimens in first-line HER2+ gastroesophageal adenocarcinoma. The company said ZIIHERA plus chemotherapy achieved a statistically significant overall survival benefit versus trastuzumab plus chemotherapy in the HERIZON-GEA-01 trial. It also said the TEVIMBRA plus ZIIHERA and chemotherapy regimen continued to show durable outcomes with a manageable safety profile. The release highlighted recent FDA approval for the regimen and said the data will be presented at a medical meeting later in 2026.

▦ Linked Companies